These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma]. Zhang K; Xu J; Yan L; Liu X; Xu F; Liu Y Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):254-7. PubMed ID: 25975908 [TBL] [Abstract][Full Text] [Related]
23. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401 [TBL] [Abstract][Full Text] [Related]
25. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]
26. Expanded Low Allele Frequency Loree JM; Dowers A; Tu D; Jonker DJ; Edelstein DL; Quinn H; Holtrup F; Price T; Zalcberg JR; Moore MJ; Karapetis CS; O'Callaghan CJ; Waring P; Kennecke HF; Hamilton SR; Kopetz S Clin Cancer Res; 2021 Jan; 27(1):52-59. PubMed ID: 33087330 [TBL] [Abstract][Full Text] [Related]
27. Clinical validation of coexisting driver mutations in colorectal cancers. Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883 [TBL] [Abstract][Full Text] [Related]
29. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients]. Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677 [No Abstract] [Full Text] [Related]
31. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575 [TBL] [Abstract][Full Text] [Related]
32. Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598 [TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F; Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630 [TBL] [Abstract][Full Text] [Related]
34. [Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes]. Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV Mol Biol (Mosk); 2017; 51(1):50-58. PubMed ID: 28251966 [TBL] [Abstract][Full Text] [Related]
35. Liquid biopsy for Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810 [No Abstract] [Full Text] [Related]
36. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458 [TBL] [Abstract][Full Text] [Related]
38. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report. Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831 [TBL] [Abstract][Full Text] [Related]
39. [Analysis of influencing factors of KRAS/NRAS/BRAF/PIK3CA gene mutation consistency in patients with advanced colorectal cancer]. Jiang HQ; Wang BL; Guo W Zhonghua Yi Xue Za Zhi; 2021 Feb; 101(6):400-404. PubMed ID: 33611888 [No Abstract] [Full Text] [Related]
40. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]